CIBC World Lowers Genentech to 'Sector Perform'

The shares rallied after good news regarding cancer drug Avastin, but analyst Matt Geller says he doesn't see any clear upside from here

CIBC World downgraded Genentech (DNA ) to sector perform from sector outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.